Your browser doesn't support javascript.
loading
Ten-year prognostic impact of target versus non-target vessel failure after STEMI. Insight from the EXAMINATION-EXTEND trial.
Verardi, Filippo Maria; Bujak, Kamil; Tolomeo, Paolo; Gómez-Lara, Josep; Jiménez-Díaz, Víctor; Jiménez, Marcelo; Jiménez-Quevedo, Pilar; Diletti, Roberto; Bordes, Pascual; Campo, Gianluca; Silvestro, Antonio; Maristany, Jaume; Flores, Xacobe; de Miguel-Castro, Antonio; Íñiguez, Andrés; Ielasi, Alfonso; Tespili, Maurizio; Lenzen, Mattie; Gonzalo, Nieves; Tebaldi, Matteo; Biscaglia, Simone; Vidal-Cales, Pablo; Ortega-Paz, Luis; Romaguera, Rafael; Gómez-Hospital, Joan Antoni; Serruys, Patrick W; Sabaté, Manel; Brugaletta, Salvatore.
Afiliación
  • Verardi FM; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
  • Bujak K; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
  • Tolomeo P; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
  • Gómez-Lara J; Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Jiménez-Díaz V; Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain; Investigación Cardiovascular, Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), Servizo Galego de Saúde-Universidade de Vigo (SERGAS-UVIGO), Vigo, Pontevedra, Spain.
  • Jiménez M; Departamento de Cardiología, Hospital Universitari Sant Pau, Barcelona, Spain.
  • Jiménez-Quevedo P; Departamento de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain.
  • Diletti R; Thoraxcenter, Rotterdam, the Netherlands.
  • Bordes P; Departamento de Cardiología, Hospital General de Alicante, Alicante, Spain.
  • Campo G; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
  • Silvestro A; Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
  • Maristany J; Departamento de Cardiología, Hospital Son Dureta, Palma de Mallorca, Spain.
  • Flores X; Departamento de Cardiología, Hospital Universitario de A Coruña, A Coruña, Spain.
  • de Miguel-Castro A; Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain.
  • Íñiguez A; Departamento de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain.
  • Ielasi A; Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
  • Tespili M; Cardiology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
  • Lenzen M; Thoraxcenter, Rotterdam, the Netherlands.
  • Gonzalo N; Departamento de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain.
  • Tebaldi M; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
  • Biscaglia S; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
  • Vidal-Cales P; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain.
  • Ortega-Paz L; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain; Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, United States.
  • Romaguera R; Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Gómez-Hospital JA; Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Serruys PW; Department of Cardiology, National University of Ireland, Galway, Ireland.
  • Sabaté M; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain.
  • Brugaletta S; Institut Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Hospital Clínic, Barcelona, Spain. Electronic address: sabrugaletta@gmail.com.
Rev Esp Cardiol (Engl Ed) ; 77(3): 215-225, 2024 Mar.
Article en En, Es | MEDLINE | ID: mdl-37506972
INTRODUCTION AND OBJECTIVES: After ST-segment myocardial infarction (STEMI), the impact of different adverse events on prognosis remains unknown. We aimed to assess very long-term predictors of patient-oriented composite endpoints (POCE) and investigate whether the occurrence of target vessel failure (TVF) vs a non-TVF event as the first event could potentially influence subsequent outcomes. METHODS: The EXAMINATION-EXTEND trial randomized STEMI patients to receive either an everolimus-eluting stent or a bare-metal stent. The follow-up period was 10 years. Predictors of POCE (a composite of all-cause death, any myocardial infarction, or any revascularization) were evaluated in the overall study population. The patients were stratified based on the type of first event (TVF-first vs non-TVF-first) and were compared in terms of subsequent POCE. TVF was defined as a composite of cardiac death, TV myocardial infarction, or TV revascularization. RESULTS: Out of the 1498 enrolled patients, 529 (35.3%) experienced a POCE during the 10-year follow-up. Independent predictors of POCE were age, diabetes mellitus, previous myocardial infarction, peripheral arterial disease, and multivessel coronary disease. The first event was a TVF in 296 patients and was a non-TVF in 233 patients. No significant differences were observed between TVF-first and non-TVF-first patients in terms of subsequent POCE (21.7% vs 39.3%, time ratio 1.79; 95%CI, 0.87-3.67;P=.12) or its individual components. CONCLUSIONS: At the 10-year follow-up, approximately one-third of STEMI patients had experienced at least 1 POCE. Independent predictors of these events were age, diabetes, and more extensive atherosclerotic disease. The occurrence of a TVF or a non-TVF as the first event did not seem to influence subsequent outcomes. TRIAL REGISTRATION NUMBER: NCT04462315.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Infarto del Miocardio con Elevación del ST / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En / Es Revista: Rev Esp Cardiol (Engl Ed) Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Infarto del Miocardio con Elevación del ST / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En / Es Revista: Rev Esp Cardiol (Engl Ed) Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: España